- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04483505
Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. (ROGABREAST)
Rogaratinib, Palbociclib and Fulvestrant in Advanced Hormone Receptor Positive, FGFR1/2/3-positive Breast Cancer: Phase I Clinical Trial Plus an Expansion Cohort
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Miguel Ángel Quintela-Fandino, MD
- Phone Number: +34917328000
- Email: mquintela@cnio.es
Study Locations
-
-
-
Lleida, Spain, 25198
- Hospital Universitari Arnau de Vilanova de Lleida
-
Madrid, Spain, 28034
- Hospital Ramon y Cajal
-
Madrid, Spain
- Hospital Universitario 12 de Octubre
-
Madrid, Spain
- Hospital Clinico San Carlos
-
Valencia, Spain
- Hospital Clínico Universitario de Valencia
-
-
Barcelona
-
Hospitalet de Llobregat, Barcelona, Spain, 08908
- Institut Català d'Oncologia - Hospital Duran i Reynals
-
-
Madrid
-
Fuenlabrada, Madrid, Spain, 28942
- Hospital Universitario de Fuenlabrada
-
Pozuelo De Alarcón, Madrid, Spain, 28223
- Hospital Quirónsalud Madrid
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women ≥18 years-old.
- Diagnostic of metastatic or locally advanced non-resectable breast cancer.
- Ability to understand and signing of the PIS/ICF for FGFR testing. FGFR testing will be performed centrally at CNIO (RNAscope and FISH).
- Ability to understand and signing the written PIS/ICF for study treatment eligibility.
- Availability of fresh tumor biopsy specimen for FGFR1/3 mRNA expression and FISH testing.
- Hormone-receptor positivity defined by at least 5% positivity of ER and/or PR (no central laboratory testing is required).
- Positivity of FGFR1/2/3 by RNA-scope and/or FISH.
- Patients must have undergone a previous hormonal treatment line for metastatic disease, with anastrozole, letrozole or exemestane, plus a cell cycle inhibitor (palbociclib, ribociclib or abemaciclib).
- Recovery of toxicities from previous regimens to equal or below tolerable grade II.
- HER2-negativity (Herceptest 0+, 1+ or 2+ with negative FISH/CISH/SISH).
- ECOG performance status of 0/1.
- Life expectancy of >24 weeks.
Adequate bone marrow, liver and renal function as assessed by laboratory requirements:
- Absolute neutrophil count (ANC) ≥ 1,500/mm3
- Hemoglobin ≥ 10 g/dL (without transfusion or erythropoietin .
- Platelet count ≥ 100,000/mm3
- Total bilirubin ≤ 1.5 × the upper limit of normal (ULN).
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN
- Alkaline phosphatase ≤ 2.5 times ULN
- Lipase and amylase ≤ 2 × ULN.
- Serum albumin ≥ 2.5 g/dl.
- Glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m2
- INR ≤ 1.5 × ULN and PTT or activated PTT (aPTT) ≤ 1.5 × ULN.
- Negative serum pregnancy test in women of childbearing potential.
- Women of reproductive potential must agree to use highly effective contraception when sexually active.
- Evaluable disease according to RECIST 1.1 criteria.
Exclusion Criteria:
- Involvement in the planning and/or conduct the study.
- Previous enrollment in the present study.
Previous or concurrent cancer except:
- Cervical carcinoma in situ.
- Treated basal-cell carcinoma or squamous cell skin cancer.
- Any other cancer curatively treated > 3 years before the first study drug administration.
- Receipt the last dose of anticancer therapy at least 21 days prior to the first dose of study drug.
- Acute toxic effects of previous anticancer chemotherapy or immunotherapy have to be normalized completely
- Anti-cancer therapy is defined as any agent or combination of agents with clinically proven anti-tumor activity
- Previous treatment with anti-FGFR directed therapies.
- Irradiation of single bony lesions with risk of fracture. Zoledronic acid or denosumab started prior to trial registration is allowed.
- Symptomatic metastatic brain or meningeal tumors.
History or current condition of an uncontrolled cardiovascular disease including any of the following conditions:
- Congestive heart failure, unstable angina (symptoms of angina at rest) or
- New-onset angina
- Myocardial infarction (MI).
- Unstable cardiac arrhythmias requiring anti-arrhythmic therapy.
- Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, must be on a stable medical regimen.
- Known human immunodeficiency virus (HIV) infection.
Active hepatitis B virus or hepatitis C infection requiring treatment.
- Patients with past HBV infection or resolved HBV infection are eligible if HBV DNA is negative.
- Patients positive for hepatitis C virus are eligible only if polymerase chain reaction is negative for HCV RNA.
- Any condition that in the opinion of the investigator would interfere with evaluation of study treatment or interpretation of patient safety or study results, or inability to comply with the study and follow-up procedures.
- Previous or concomitant participation in another clinical study with investigational medicinal products.
- Active tuberculosis.
- Clinically active infections.
- Treatment with therapeutic oral or i.v. antibiotics.
- Patients receiving prophylactic antibiotics are eligible.
- Seizure disorder requiring medication.
- History of organ allograft.
- Evidence or history of bleeding diathesis or coagulopathy.
- Any hemorrhage / bleeding event CTCAE v.5.0 ≥ Grade 3.
- Serious, non-healing wound, ulcer or bone fracture.
- Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation.
- Any malabsorption condition.
- Current diagnosis of any retinal disorders including retinal detachment, retinal pigment epithelial detachment (RPED), serous retinopathy or retinal vein occlusion.
- Peripheral sensory neuropathy of CTCAE v.5.0 Grade 2 or higher.
- Current evidence of endocrine alteration of calcium phosphate homeostasis.
- Concomitant therapies that are known to increase serum phosphate levels.
- Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.
- Breast-feeding.
- Use of strong inhibitors of CYP3A4 and strong inducers of CYP3A4.
- Autologous bone marrow transplant or stem cell rescue.
- Major surgery, open biopsy or significant traumatic injury.
- Renal failure requiring peritoneal dialysis or hemodialysis.
- Systolic/diastolic blood pressure ≤ 100/60 mmHg and concurrent heart rate ≥ 100/min.
- Inability to swallow oral tablets.
- Close affiliation with the investigational site; e.g. a close relative of the investigator or a dependent person.
- Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
- Arterial or venous thrombotic events or embolic events such as cerebrovascular accident, deep vein thrombosis or pulmonary embolism.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rogaratinib + palbociclib + fulvestrant
|
Patients will receive rogaratinib, palbociclib and fulvestrant in cycles of 28 days. Escalation Dose will follow a classic 3+3 schedule.The planned dose-levels are as follows:
Treatment will continue until disease progression. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recommended Phase 2 Dose
Time Frame: 2 months
|
Highest dose at which <1 out of 6 patients experience a DLT.
|
2 months
|
Incidence of Treatment-Emergent Adverse Event
Time Frame: 2 years
|
Percentage of patients with each adverse event.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival
Time Frame: 2 years
|
Time from the date of first dose of study treatment to the date of progression or death (from any cause).
|
2 years
|
Pharmacokinetic interactions of fulvestrant and palbociclib over rogaratinib metabolism.
Time Frame: 2 years
|
Plasmatic levels of fulvestrant, palbociclib and rogaratinib
|
2 years
|
Pharmacodynamic markers levels of FGFR1 Blockade
Time Frame: 2 years
|
Plasma levels of phosphate and FGF23.
|
2 years
|
Response rate
Time Frame: 1 year
|
Percentage of patients that achieve response according to RECIST 1.1 criteria.
|
1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Miguel Ángel Quintela-Fandino, Centro Nacional de Investigaciones Oncológicas
- Principal Investigator: Luis Manso, MD, Hospital Universitario 12 de Octubre
- Principal Investigator: Ramón Colomer i Bosch, Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Site
- Breast Diseases
- Neoplasms
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protein Kinase Inhibitors
- Hormone Antagonists
- Estrogen Antagonists
- Estrogen Receptor Antagonists
- Fulvestrant
- Palbociclib
Other Study ID Numbers
- ROGABREAST
- 2020-000055-12 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hormone Receptor Positive Malignant Neoplasm of Breast
-
Sunnybrook Health Sciences CentreGenomic Health®, Inc.CompletedHormone Receptor Positive Malignant Neoplasm of BreastCanada
-
Stemline Therapeutics, Inc.CompletedHormone Receptor Positive Malignant Neoplasm of BreastUnited States
-
Virginia Polytechnic Institute and State UniversityCarilion ClinicCompletedHormone Receptor Positive Malignant Neoplasm of BreastUnited States
-
Seoul National University HospitalCompletedHormone Receptor Positive Malignant Neoplasm of BreastKorea, Republic of
-
Organisation for Oncology and Translational ResearchUnknownHormone Receptor Positive Malignant Neoplasm of BreastChina
-
Amsterdam UMC, location VUmcNovartis; Borstkanker Onderzoek GroepUnknownMetastatic Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of BreastNetherlands
-
Peking Union Medical College HospitalNot yet recruitingBreast Diseases | Metastatic Breast Cancer | HER2-positive Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer Female | Hormone Receptor Positive Tumor
-
Fuzhou General HospitalNot yet recruitingBreast Diseases | Metastatic Breast Cancer | HER2-positive Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer Female | Hormone Receptor Positive TumorChina
-
Oana Danciu, MDPfizer; Big Ten Cancer Research ConsortiumActive, not recruitingMetastatic Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Estrogen Receptor Positive Breast Cancer | Progesterone Receptor Positive TumorUnited States
-
Columbia UniversityRecruitingTriple Negative Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of BreastUnited States
Clinical Trials on Combination, Rogaratinib + palbociclib + fulvestrant
-
BayerCompleted
-
Jiangsu Alphamab Biopharmaceuticals Co., LtdTerminatedHER2-positive Metastatic Breast CancerChina
-
PfizerCompletedBreast NeoplasmsQatar, United Arab Emirates, Saudi Arabia
-
Royal Marsden NHS Foundation TrustPfizer; Hoffmann-La RocheRecruitingAdvanced Breast Cancer | Metastatic Breast Cancer | ER+ Breast CancerUnited Kingdom
-
Assistance Publique - Hôpitaux de ParisUnknownBreast Cancer | Metastasis | HR+/HER2-negative Breast Cancer
-
PfizerRecruitingBreast Cancer | Small Cell Lung Cancer | Ovarian CancerChina, United States, Japan, Mexico
-
Fundacion OncosurPfizer; Apices Soluciones S.L.; Pierre Fabre Ibérica, S.A.CompletedTriple Negative Breast CancerSpain
-
PfizerActive, not recruiting
-
International Cancer Research Group, United Arab...Pfizer; AstraZeneca; Genomic Health®, Inc.CompletedBreast Neoplasm FemaleUnited Arab Emirates, Algeria, Egypt, Jordan, Lebanon, Morocco, Saudi Arabia, Tunisia
-
Cancer Institute and Hospital, Chinese Academy...RecruitingHormone Receptor Positive Advanced Breast CancerChina